Curis Lifesciences Limited Link 
Allotment
Curis Lifesciences IPO will open on November 7, 2025, and close on November 11, 2025. It is a Book Built Issue through which the company aims to raise approximately ₹27.52 crores via a fresh issue of equity shares, each with a face value of ₹10.
The IPO price band is set between ₹120 and ₹128 per share. The issue allocation is divided as 35% for retail investors, 50% for QIBs, and 15% for HNIs. Curis Lifesciences IPO is scheduled to list on NSE on November 14, 2025, with the allotment expected on November 12, 2025.
The company posted a revenue of ₹49.65 crores in FY2025, up from ₹35.87 crores in FY2024. Profit for FY2025 stood at ₹6.11 crores, compared to ₹4.87 crores in FY2024. Based on these financials, the IPO is recommended for long-term investment.
₹128
0%
Open
₹128
HIgh - Low
₹128
Previous Close
₹128
Total Traded Value
0
52 Weeks High
₹128
52 Weeks Low
₹128
Updates On
Nov 5, 2025
IPO. Open
Nov 7, 2026
IPO. Close
Nov 11, 2026
IPO. Price
₹128.00
IPO Market price
₹103.48 Cr
IPO Details
| IPO Date | 14 Nov |
| IPO Listing Date | 14 Nov |
| IPO Face Value | ₹10.00 per share |
| IPO Price Range | ₹128.00 |
| IPO Issue Size | 21,50,000 shares |
| IPO Sale Type | Fresh Capital |
| Employee Discount | - |
| IPO Issue Type | Bookbuilding IPO |
| IPO Listing | NSE SME Platform |
| Share Holding Pre Issue | 59,34,434 shares |
IPO Timeline
| IPO Open Date | 7 Nov |
| IPO Close Date | 11 Nov |
| IPO Allotment (Tentative) | 12 Nov |
| Refunds | 13 Nov |
| Credit to Demat Account | 13 Nov |
| IPO Listing Date | 14 Nov |
IPO Reservation
| Category | Offer |
|---|---|
| QIB Shares Offered | 10,17,000 |
| NII (HNI) Shares Offered | 3,09,000 |
| Retail Shares Offered | 7,16,000 |
IPO Lot Size
Investors can bid for a minimum of 2,000 shares, with additional shares in multiples of 1,000.
| Application | Lots | Share | Amount |
|---|---|---|---|
| Retail (Min) | 2 | 2,000 | ₹2,56,000 |
| Retail (Max) | 2 | 2,000 | ₹2,56,000 |
| S-HNI (Min) | 3 | 3,000 | ₹3,84,000 |
| S-HNI (Max) | 7 | 7,000 | ₹8,96,000 |
| B-HNI (Min) | 8 | 8,000 | ₹10,24,000 |
Curis Lifesciences Limited, incorporated in 2010, is a pharmaceutical company engaged in the development, manufacturing, and distribution of a broad range of pharmaceutical products.
The company operates both domestically and internationally, manufacturing products on a loan license or contract basis, as well as marketing its own brand. It serves over 100 corporate clients through contract manufacturing and two clients for its own brand marketing in Yemen and Kenya.
Product Portfolio:
* General pharmaceutical tablets and capsules
* Oral liquids
* External preparations
* Sterile ophthalmic ointments
Curis Lifesciences runs a modern manufacturing facility in Sanand, Gujarat, ensuring strict quality control for safety and efficacy.
Key Highlights & Competitive Strengths:
* Experienced promoters and management team
* Wide product range
* Strategically located manufacturing facility
* Scalable business model
* Strong quality assurance processes
As of July 31, 2025, the company employed 95 permanent staff. Curis Lifesciences combines contract manufacturing with its own brand operations, providing reliable pharmaceutical solutions to clients both in India and abroad.
Company Financials (Consolidated)
| Assets | 56.29 | 42.53 | 33.88 |
| Total Income | 19.51 | 49.65 | 35.87 |
| Profit After Tax | 2.87 | 6.11 | 4.87 |
| EBITDA | 4.24 | 9.54 | 8.39 |
| NET Worth | 19.1 | 16.23 | 5.87 |
| Reserves and Surplus | 13.16 | 10.29 | 5.37 |
| Total Borrowing | 15.32 | 15.62 | 17.09 |
Key Performance Indicator (KPI)
| ROE | 55.25% |
| ROCE | 27.83% |
| Debt/Equity | 0.96 |
| RoNW | 37.62% |
| PAT Margin | 12.43% |
| EBITDA Margin | 19.41% |
| Price to Book Value | 12.64 |
IPO Objects of the Issue
| S.No. | Objects of the ipo Resources Detail | IPO Amount |
|---|---|---|
| 1 | Funding capital expenditure requirements for the purchase of equipment/machineries | - |
| 2 | To meet out the expenses of Working Capital Requirement | 11.25 |
| 3 | To meet out the General Corporate Purposes; | 2.85 |
| 4 | Offer for Sale (OFS) | - |
Contact Details
Curis Lifesciences Ltd.
PF-23, GIDC Sanand – II,
Industrial Estate,
Sanand
Ahmedabad, Gujarat, 382110
Phone: +91 99045 22543
Email: cs@curisls.com
Website: https://curisls.com/
Detail Registrar
IPO Registrar
MUFG Intime India Pvt.Ltd.
Phone: +91-22-4918 6270
Email: curislifesciences.smeipo@in.mpms.mufg.com
Website: https://in.mpms.mufg.com/Initial_Offer/public-issues.html
Curis Lifesciences IPO is a fresh issue of 21.50 lakh shares raising about ₹28 crore, mainly for facility upgrades, working capital needs, debt repayment, and overseas product registrations.
The IPO opened on November 7, 2025, and closed on November 11, 2025. Shares were listed on the NSE SME platform on November 14, 2025.
The issue price was fixed at ₹128 per share with a lot size of 1,000 shares. Retail investors had to apply for a minimum of 2,000 shares costing ₹2,56,000.
In FY2025, Curis Lifesciences reported revenue of ₹49.65 crore and PAT of ₹6.11 crore, showing steady growth supported by improving margins and strong return ratios.
The company operates a scalable pharma model combining contract manufacturing and own-brand marketing, supported by experienced management, diversified products, quality systems, and a modern Gujarat-based manufacturing facility.
Compare:
